Pharma-major, Lupin Limited, announced that it has received tentative approval for its Empagliflozin and Linagliptin tablet in the strengths of 10 mg/5 mg and 25 mg/5 mg from United States Food and Drug Administration (USFDA), to commercialise a generic version of Glyxambi tablets, of Boehringer Ingelheim Pharmaceuticals, Inc.